Low-to-moderate load power and strength training for men with metastatic prostate cancer
Official title: Low to Moderate Load Power Training as an Exercise Intervention for Men With Metastatic Prostate Cancer Undergoing Androgen Deprivation Therapy.
Run by University of Alicante · NCT07572760 · Data updated 2026-11-12
This trial will test whether a twice-weekly, supervised low-to-moderate load power training program can improve fitness and quality of life for men with metastatic prostate cancer who are on androgen deprivation therapy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years and up |
| Sex | Men only |
| Enrollment | 66 (estimated) |
| Sponsor | University of Alicante Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (San Vicent del Raspeig, Alicante) |
| Status | Recruiting |
| Started | April 10, 2024 |
| Main results expected | November 10, 2026 |
| Study ends | December 10, 2026 |
| Registry record updated | May 7, 2026 |
| Trial ID | NCT07572760 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are functionally independent men with histologically confirmed metastatic prostate adenocarcinoma limited to bone and/or lymph nodes who are on ADT combined with an ARSI and receiving bone-protective therapy.
✕Probably not a fit
Patients with visceral metastatic disease, significant functional dependence, or those not receiving the specified systemic and bone-protective therapies are unlikely to benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Men with metastatic prostate adenocarcinoma who are functionally independent and receiving ADT plus an ARSI are assigned to either a supervised exercise program twice weekly for six months or to routine care. The intervention uses low-to-moderate loads focused on power, strength, endurance, and balance, with adaptations made to protect sites of bone or lymph node metastasis. Outcomes include patient-reported health-related quality of life and objective tests of power, strength, endurance, and balance performed at baseline and after the intervention. Safety monitoring and bone-protective measures are integrated throughout the program.
Why it matters
Potential benefit: If successful, the program could improve muscle strength, physical function, and overall quality of life for men on ADT with bone or lymph node metastases.
How similar studies have gone: Related resistance and power training programs have shown benefits for strength and quality of life in men on ADT, but supervised low-to-moderate power training specifically in men with metastatic bone or nodal disease has been less extensively studied.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histopathologically confirmed diagnosis of prostate adenocarcinoma. • Metastatic hormone-sensitive prostate cancer (mHSPC), defined as: * Presence of metastases at initial diagnosis (synchronous mHSPC), or * Development of metastatic disease following prior treatment with curative intent (surgery and/or radiotherapy) (metachronous mHSPC). * Evidence of progression to castration-resistant prostate cancer (CRPC). * Ongoing treatment with a doublet regimen consisting of standard androgen deprivation therapy (ADT) in combination with an androgen receptor signaling inhibitor (ARSI), initiated prior to study enrollment. * Receipt of bone-protective therapy, including calcium and vitamin D supplementation in combination with bisphosphonates. * Presence of metastatic involvement limited to bone and/or lymph nodes. * Functionally independent in activities of daily living. Exclusion Criteria: * Evidence of visceral metastatic disease. * Current or prior treatment with a triplet regimen that includes chemotherapy. * History of pathological fracture.
Where it's running
-
University of Alicante
San Vicent del Raspeig, Alicante, Spain Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
JNJ-101556143 plus Best Supportive Care for metastatic prostate cancer
This study tests whether adding JNJ-101556143 to standard supportive care helps people with metastatic, hormone-resistant prostate cancer live longer than those who receive placebo plus supportive care.
-
Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer
This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.
-
Testing JNJ-101556143 in men with advanced prostate cancer that no longer responds to hormone therapy
This study tests JNJ-101556143 in men with metastatic, hormone-resistant prostate cancer to see if tumors shrink or disappear.
-
New treatment option for advanced prostate cancer using JNJ-98768111
A first-in-human study tests JNJ-98768111 to see how safe it is and find the best dose for people with advanced prostate cancer who have already tried other therapies.
-
Benchmarking AI language models against tumor boards for oncology treatment decisions
This project tests whether frontier AI language models can match the treatment recommendations of multidisciplinary tumor boards for common cancers using standardized synthetic cases.
-
FX-111 safety and pharmacokinetics in metastatic castration-resistant prostate cancer
This study tests whether FX-111 is safe and can help treat metastatic castration-resistant prostate cancer in adult men.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.